Sanofi is negotiating a deal to sell a controlling stake in its Consumer Healthcare division enabling the French firm to retain a substantial share of the business.
Private Equity Poised To Take Control Of Opella But Sanofi Will Retain Sizable Stake
Control of Sanofi Consumer Healthcare – recently rebranded as Opella – may soon pass to US private-equity firm CD&R but the French firm looks set to retain a substantial stake in a business which has some big Rx-to-OTC switches in the pipeline.
More from Deals
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.
• By
Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.
• By
A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.
More from Business
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”
• By
A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.
• By
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.